Although its clinical use in Europe dates almost 10 years, nebivolol is a β-blocker that has
been only recently introduced in the US market. Like carvedilol, nebivolol belongs to the …

Beta blockers have been used in the treatment of cardiovascular conditions for decades.
Despite a long history and status as a guideline-recommended treatment option for …

Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …

Hypertension is one of the leading risk factors for morbidity and mortality in patients with
cardiovascular and cerebrovascular diseases and renal impairment. It also leads to target …

Nebivolol is a third-generation β-adrenergic receptor antagonist (β-blocker) with high
selectivity for β 1-adrenergic receptors. In addition, it causes vasodilatation via interaction …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Острый инфаркт миокарда является тяжелым сердечно-сосудистым заболеванием. В
ряде исследований выявлена зависимость течения инфаркта миокарда не только от …

Nebivolol is a third generation beta-blocker, which can be distinguished from other beta-
blockers by its hemodynamic profile. It combines beta-adrenergic blocking activity with a …

Endothelin-1 (ET-1) plays a major role in the pathophysiology of hypertension and its
associated cardiovascular risk. We tested the hypothesis that chronic nebivolol treatment …

Hypertension is the number one diagnosis made by primary care physicians, placing them
in a unique position to prescribe the antihypertensive agent best suited to the individual …